Nexsen Expands GBS Diagnostic Platform into Neonatal Care with AEA-Funded Project

Nexsen Limited ( (AU:NXN) ) has issued an update.

Nexsen Limited has secured a role as commercialisation partner in a more than $1 million project with RMIT University, funded in part by a $500,000 non-dilutive grant from the Australian Government’s Australia’s Economic Accelerator Ignite program, to adapt its existing maternal GBS Rapid Sensor into a point-of-care diagnostic for neonatal use. The initiative extends Nexsen’s GBS platform into a significantly larger global market by targeting early- and late-onset GBS infections in newborns, with development costs largely covered by grant and in-kind contributions, thereby preserving Nexsen’s capital, accelerating progress toward clinical validation, and reinforcing the scalability of its technology in line with national priorities for advanced medical manufacturing.

More about Nexsen Limited

Nexsen Limited is an Australian medical diagnostics company focused on rapid point-of-care testing, with a core platform built around its Group B Streptococcus (GBS) Rapid Sensor technology. The company is targeting major unmet needs in maternal and neonatal care by developing scalable, biomarker-based diagnostic devices for use across multiple clinical settings, including antenatal screening and now newborn testing.

Average Trading Volume: 301,597

See more insights into NXN stock on TipRanks’ Stock Analysis page.